Business Context and Reporting Period
Company: XORTX Therapeutics Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: XORTX is a late clinical-stage biotechnology company focused on developing therapies for diseases modulated by aberrant purine and uric acid metabolism. Its primary programs include XRx-026 (gout), XRx-008 (autosomal dominant polycystic kidney disease), XRx-101 (acute kidney injury associated with respiratory virus infection), and XRx-225 (type 2 diabetic nephropathy). The company has no products approved for commercial sale and has not generated any revenue to date.
Key Financial Metrics
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,656,304) | $(3,313,346) | $(2,158,065) |
| Accumulated Deficit | $(23,824,557) | $(21,168,253) | $(17,854,907) |
| Cash and Cash Equivalents (Year End) | $864,514 | $2,473,649 | $3,447,665 |
| Net Cash Used in Operating Activities | $(2,768,723) | $(3,678,648) | $(6,583,165) |
| Net Cash Provided by Financing Activities | $1,427,544 | $2,779,509 | $(361,044) |
| Total Assets | $2,683,530 | $4,094,527 | N/A |
| Total Liabilities | $599,071 | $757,990 | N/A |
Note: The filing text does not provide explicit gross margin or operating margin data as the company has no revenue. The company reported a significant fair value gain on derivative warrant liabilities of $564,000 in 2025, which reduced the reported net loss.
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss decreased by approximately 19.8% from 2024 to 2025, primarily driven by a $564,000 gain from the fair value adjustment of derivative warrant liabilities and a reduction in investor relations expenses.
- Cash Position: Cash and cash equivalents declined by approximately 65% year-over-year, from $2.47 million in 2024 to $864,514 in 2025, reflecting continued operational burn and reduced financing proceeds compared to the prior year.
- Financing Activity: In 2025, the company raised approximately $2.26 million in gross proceeds from equity issuances (private placements and registered direct offerings), compared to $3.5 million in 2024.
- Liabilities: Total liabilities decreased from $757,990 in 2024 to $599,071 in 2025, largely due to the revaluation of derivative warrant liabilities from $572,000 to $8,000.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Strategic Focus: Management is prioritizing the XRx-026 program for gout, aiming to file a New Drug Application (NDA) via the FDA's 505(b)(2) pathway. The company estimates this program could address a market opportunity of approximately $700 million annually.
- Acquisition: The company entered into a binding term sheet to acquire a renal anti-fibrotic therapeutic program (VB4-P5) from Vectus Biosystems Limited for $3.0 million in shares. Closing was extended to March 31, 2026.
- Capital Needs: The company explicitly states it will require substantial additional funding to continue operations and advance clinical trials. It anticipates continuing to incur losses for the foreseeable future.
Risks and Contingencies
- Going Concern: The independent auditor has issued a "Going Concern" opinion, noting a material uncertainty regarding the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00). It has been granted an extension until April 13, 2026, to regain compliance.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting related to the period-end closing process and management review controls, which remained unremediated as of December 31, 2025.
- Regulatory Risk: Success depends on obtaining FDA approval for product candidates, which is uncertain. The company relies on third-party manufacturers and CROs, introducing supply chain and execution risks.
Key Facts for Investor Verification
- Cash Runway: Verify the current cash balance and burn rate to assess the immediate need for capital raising, given the $864k cash balance and $2.7M operating cash burn in 2025.
- Nasdaq Status: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price requirement by the April 13, 2026 deadline to avoid delisting.
- Acquisition Closing: Confirm the closing of the Vectus Biosystems acquisition and the issuance of the $3.0 million in shares, which will impact share count and dilution.
- Internal Control Remediation: Review subsequent filings for updates on the remediation of the material weakness in internal controls over financial reporting.
- Derivative Liability Volatility: Note that net income/loss is significantly impacted by non-cash fair value adjustments of derivative warrant liabilities, which can distort the view of operational performance.